Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD

Inflammatory Bowel Diseases · Published 2026-07-07 · DOI 10.1093/ibd/izag143

Authors (5)

Sama Anvari, Wasuwit Wanchaitanawong, Xin Xiong, Tianxi Cai, Ashwin N Ananthakrishnan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Anvari, S., Wanchaitanawong, W., Xiong, X., et al. (2026). Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag143

Related articles